NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free ITRM Stock Alerts $1.69 +0.12 (+7.64%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.52▼$1.7250-Day Range$1.24▼$1.8752-Week Range$0.62▼$2.50Volume106,274 shsAverage Volume496,807 shsMarket Capitalization$27.77 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Iterum Therapeutics alerts: Email Address Iterum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside255.0% Upside$6.00 Price TargetShort InterestHealthy7.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.75) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.20 out of 5 starsMedical Sector753rd out of 908 stocksPharmaceutical Preparations Industry350th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingIterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIterum Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.50% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently decreased by 2.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITRM. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Iterum Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.21% of the stock of Iterum Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iterum Therapeutics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Iterum Therapeutics Stock (NASDAQ:ITRM)Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More ITRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITRM Stock News HeadlinesApril 25, 2024 | americanbankingnews.comIterum Therapeutics (NASDAQ:ITRM) vs. RedHill Biopharma (NASDAQ:RDHL) Head to Head ContrastApril 2, 2024 | finance.yahoo.comIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call TranscriptApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 30, 2024 | seekingalpha.comIterum Therapeutics plc (ITRM) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Iterum Therapeutics PLC Earnings CallMarch 28, 2024 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comIterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024April 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 15, 2024 | globenewswire.comIterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatMarch 12, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 6, 2024 | finance.yahoo.comIterum Therapeutics Provides Business UpdateFebruary 28, 2024 | investing.comIterum Therapeutics PLC (ITRM)February 24, 2024 | msn.comIterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63February 1, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLCFebruary 1, 2024 | msn.comIterum Shareholders Reject Board’s Share Issuance ProposalJanuary 31, 2024 | msn.comIterum Therapeutics Announces Triumph in Phase 3 uUTI TrialJanuary 30, 2024 | msn.comWhy Iterum Therapeutics Stock Is Trending TodayJanuary 30, 2024 | msn.comIterum meets main goal in late trial for uUTI treatment with oral sulopenemJanuary 30, 2024 | markets.businessinsider.comIterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary EndpointJanuary 30, 2024 | marketwatch.comIterum Therapeutics Says UTI Drug Trial Met Primary EndpointJanuary 30, 2024 | marketwatch.comIterum Therapeutics Shares Surge on Positive UTI Drug Trial ResultsJanuary 30, 2024 | finance.yahoo.comIterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsDecember 28, 2023 | msn.comInsiders Buying Iterum Therapeutics And 3 Other Stocks Under $3November 29, 2023 | msn.comIterum Therapeutics director discloses purchase of 20K sharesNovember 15, 2023 | finance.yahoo.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call TranscriptNovember 15, 2023 | finance.yahoo.comQ3 2023 Iterum Therapeutics PLC Earnings CallSee More Headlines Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITRM CUSIPN/A CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+255.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-664.00% Return on Assets-87.64% Debt Debt-to-Equity Ratio3.63 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-3.52Miscellaneous Outstanding Shares16,430,000Free Float15,540,000Market Cap$27.77 million OptionableNot Optionable Beta2.36 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Corey N. Fishman (Age 59)President, CEO & Director Comp: $1.37MMs. Judith M. Matthews (Age 54)Chief Financial Officer Comp: $778.82kDr. Michael W. Dunne M.D. (Age 64)Strategic Advisor & Director Comp: $168.15kDr. Sailaja Puttagunta M.D. (Age 55)Chief Medical Officer Comp: $755.89kMr. Tom Loughman Ph.D.Senior Vice President of Technical OperationsMs. Louise BarrettSenior Vice President of Legal Affairs & SecretaryDr. Steven I. Aronin M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsDURECTNASDAQ:DRRXEyenoviaNASDAQ:EYENQilian International Holding GroupNASDAQ:QLILipocineNASDAQ:LPCNVaxxinityNASDAQ:VAXXView All CompetitorsInsidersMichael W DunneBought 25,000 shares on 12/22/2023Total: $35,000.00 ($1.40/share)Michael W DunneBought 20,000 shares on 11/22/2023Total: $40,600.00 ($2.03/share)Corey N FishmanBought 10,000 shares on 11/20/2023Total: $15,900.00 ($1.59/share)View All Insider Transactions ITRM Stock Analysis - Frequently Asked Questions Should I buy or sell Iterum Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ITRM shares. View ITRM analyst ratings or view top-rated stocks. What is Iterum Therapeutics' stock price target for 2024? 1 analysts have issued twelve-month price targets for Iterum Therapeutics' stock. Their ITRM share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 255.0% from the stock's current price. View analysts price targets for ITRM or view top-rated stocks among Wall Street analysts. How have ITRM shares performed in 2024? Iterum Therapeutics' stock was trading at $1.97 at the start of the year. Since then, ITRM stock has decreased by 14.2% and is now trading at $1.69. View the best growth stocks for 2024 here. When is Iterum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ITRM earnings forecast. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics plc (NASDAQ:ITRM) posted its earnings results on Thursday, March, 28th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.08. When did Iterum Therapeutics' stock split? Iterum Therapeutics shares reverse split on the morning of Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN). When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITRM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
